InvestorsHub Logo
Followers 85
Posts 5198
Boards Moderated 1
Alias Born 01/23/2010

Re: None

Tuesday, 03/29/2011 5:33:57 PM

Tuesday, March 29, 2011 5:33:57 PM

Post# of 870
Merck selected Newcardio inc, NWCI, for it's QTinno® product, for use for their automated cardiac safety solution, for two Phase I drug safety studies.

Fully automated ECG analysis, empowered by QTinno, will be delivered by the ECG core lab of a top 3 Clinical Research Organization (CRO) under the terms of an existing Master Services Agreement with NewCardio.

The studies start in March and are expected to be complete by June of 2011.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News